Total Voting Rights

RNS Number : 0458T
Hutchison China Meditech Limited
30 December 2016
 

 

 

 

 

 

Total Voting Rights

 

 

London: Friday, December 30, 2016: For information purposes, Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) hereby notifies the market that as at December 30, 2016, the issued share capital of Chi-Med consisted of 60,705,823 ordinary shares of US$1.00 each, with each share carrying one right to vote and with no shares held in treasury.

 

The above figure of 60,705,823 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, Chi-Med under the Financial Conduct Authority's Disclosure Rules and Transparency Rules.

 

For illustrative purposes only, the 60,705,823 ordinary shares would be equivalent to 60,705,823 CREST depositary interests (each equating to one ordinary share) which are traded on AIM or, if the CREST depositary interests were converted in their entirety, equivalent to 121,411,646 American depositary shares (each equating to one-half of one ordinary share) which are traded on Nasdaq.

 

 

About Chi-Med

 

Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products.  Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market.  Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

 

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001).  For more information, please visit: www.chi-med.com.

 

 

Contacts

 

Investor Enquiries

 

 

Christian Hogg, CEO

+852 2121 8200

 

 

 

 

International Media Enquiries

 

 

Anthony Carlisle,
Citigate Dewe Rogerson

+44 7973 611 888 (Mobile)

anthony.carlisle@cdrconsultancy.co.uk

 

 

 

U.S. Based Media Enquiries

 

 

Brad Miles, BMC Communications

+1 (917) 570 7340 (Mobile)

bmiles@bmccommunications.com

 

 

 

Susan Duffy, BMC Communications

+1 (917) 499 8887 (Mobile)

sduffy@bmccommunications.com

 

 

 

Investor Relations

 

 

Matt Beck, The Trout Group

+1 (917) 415 1750 (Mobile)

mbeck@troutgroup.com

 

 

 

David Dible,

Citigate Dewe Rogerson 

+44 7967 566 919 (Mobile)

david.dible@citigatedr.co.uk

 

 

 

Panmure Gordon (UK) Limited

 

 

Richard Gray / Andrew Potts

+44 (20) 7886 2500

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TVREANAEDFEKFEF
UK 100

Latest directors dealings